利蒙宁是一种天然的ERK2激动剂,可以防止缺血性急性损伤
Xianke Zhou1, Yadie Xiang1, Dier Li1
1Division of Nephrology, Nanfang Hospital, Southern Medical University; State Key Laboratory of Organ Failure Research; National Clinical Research Center for Kidney Disease; Guangdong Provincial Institute of Nephrology; Guangdong Provincial Key Laboratory of Renal Failure Research, Guangzhou, 510515, China.
International journal of biological sciences
|June 16, 2023
概括
利蒙尼是一种天然化合物,激活ERK2,保护脏免受急性损伤 (AKI). 这一发现通过促进修复和减少细胞死亡,为病提供了潜在的新疗法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 急性损伤 (AKI) 是一个重要的临床挑战,治疗选择有限.
- 细胞外信号调节激酶 (ERK) 途径对于脏的修复和再生至关重要.
- 目前没有针对ERK治疗病的特定激活剂.
研究的目的:
- 为了识别和表征激活ERK2的天然化合物,用于潜在的AKI治疗.
- 阐明利蒙因减轻AKI的机制.
主要方法:
- 结构分析和分子对接,以确定利蒙因的结合标.
- 生物物理试验 (细胞热转移试验,微量热泳) 来确认利蒙因-ERK2相互作用.
- 在AKI条件下进行体内,体外和体外研究,以评估利蒙对功能和管状细胞的影响.
主要成果:
- 利蒙宁被确定为具有高结合亲和度的自然ERK2激活剂.
- 在缺血性AKI模型中,用利蒙因进行预处理显著保留了功能.
- 利蒙尼激活了ERK信号通路,促进了管状细胞的增殖,并减少了AKI模型中的亡.
- 阻断ERK信号消除了利蒙因对低氧诱导的管状细胞死亡的保护作用.
结论:
- 利蒙宁是一种新型ERK2激活剂,具有预防或减轻AKI的治疗潜力.
- 用利蒙因准ERK通路为治疗脏疾病提供了一个有前途的策略.
相关概念视频
Acute Kidney Injury II: Pathophysiology
37
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
37
Acute Kidney Injury IV: Diagnostic Studies and Prevention
40
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
40
Acute Kidney Injury I: Introduction
38
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
38
Antihypertensive Drugs: Direct Renin Inhibitors
709
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
709
Acute Kidney Injury V: Interprofessional Care
30
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30
Acute Kidney Injury III: Clinical Manifestations
44
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
44


